Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis

Annals of the Rheumatic Diseases

Volumn 67, Issue 5, 2008, Pages 723-

  Sangle, V S ^a   Sangle, S R ^a   D'Cruz, D P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM; CREATINE KINASE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; JO 1 ANTIBODY; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTON PUMP INHIBITOR;

ADULT; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYCOSIS; DISEASE COURSE; DYSPEPSIA; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LETTER; LUNG FUNCTION TEST; MUSCLE BIOPSY; MUSCLE WEAKNESS; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MIDDLE AGED; PREDNISOLONE;

EID: 42449117957     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073221     Document Type: Letter

References (10)

1. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003;27:407-25.
2. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 2002;28:723-41.
3. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed M, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
4. Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle Nerve 1997;20:651-64.
5. Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol 2006;6:550-6.
6. Pisoni C, Cuadrado MJ, Khamashta MA, Hughes GRV, D'Cruz DP. Mycophenolate mofetil treatment in resistant myositis. Rheumatology 2007;46:516-18.
7. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65:1233-6.
8. Goldenberg MM. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther 1999;21:1837- 52.
9. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 126) blocks TNF-dependent nuclear factor-κB and gene expression. J Immunol 1999;162:2095-102.
10. Lange U, Piegsa M, Muller-Ladner U, Strunk J. Anti-Jo-1 antibody positive polymyositis, successful therapy with leflunomide. Autoimmunity 2006;39:261-4.